Daily Equity Reports 22 Jan 2019

1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 22 NDJANUARY 2019 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET CLOSE PREVIOUS ! INDIAN EQUITY BENCHMARK - Benchmark indices ended higher on Monday but gave up some of its intraday gains in the last hour of trading. Nifty finished above 10,950 level NIFTY ASIAN MARKET with the help of energy stocks led by Reliance Industries. CLOSE PREVIOUS The Sensex was up 192.35 points at 36,578.96, while Nifty was up 54.90 points at 10, 961.90. About 930 shares have NIKKEI advanced, 1651 shares declined, and 155 shares are unchanged. GLOBAL FACE 2124.61 2124.28 SECTORIAL INDICES CLOSE CHANGE (%) ! Asian Market - Asian markets finished higher today with shares in China leading the region. The Shanghai Composite is CNX 100 0.39 S&P CNX 500 9155.30 0.17 up 0.56% while Hong Kong's Hang Seng is up 0.39% and Japan's Nikkei 225 is up 0.26%. 4828.30 -0.52 ! CNX 200 5756.05 0.26 U.S. Market – North and South American markets finished broadly higher on Friday with shares in U.S. leading the region. The S&P 500 is up 1.32% while Brazil's Bovespa is up 0.28 TOP GAINERS 0.78% and Mexico's IPC is up 0.70%. CLOSE CHANGE (%) 4.28 RELIANCE 1235.00 ! 2.73 KOTAKBANK 1274.00 European markets - European markets are mixed. The FTSE 100 is higher by 0.25%, while the DAX is leading the CAC 40 2.08 BAJAJFINSV 6380.00 lower. They are down 0.41% and 0.13% respectively. 2.00 SUNPHARMA 398.55 TOP LOSERS CLOSE CHANGE (%) 2783.00 YESBANK 191.2 WIPRO 336.45 MARUTI 7188.00 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE TREND BULLISH STRATEGY SCRIPT CLOSE (%) 4.28 RELIANCE 1235.00 PIVOT POINTS S3 10741 S2 10843 R1 11004 R2 11046 R3 11148 1.86 BIOCON 663.20 10902 10945 1.61 INFY 742.75 S1-10902 S2-10843 R1-11004 R2-11046 1.47 GAIL 327.90 MARKET MOVERS DOWNSIDE CLOSE (%) -6.68 32.85 VODAFONE -3.99 2783.00 HEROMOTO -3.20 APOLLOHOSP 1315.00 -3.73 YESBANK 192.10 NET BUY (CR.) NET SELL (CR) STRATEGY SELL ON RISE 3458.07 BEARISH PIVOT POINTS P 27563 DII 3281.77 S3 S1 27451 R1 27676 R2 R3 28014 27111 27337 27788 RESISTANCE NSE TOTALS ADVANCE BANK NIFTY S NIFTY BANK NIFTY 9 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report MARKET TALKS Lupin receives USFDA approval for! gSynthroid ! SEBI rejects Larsen & Toubro's Rs9,000cr buyback offer SEBI rejected Larsen & Toubro's Rs9,000cr share buyback plan, citing compliance issues over its post- buyback debt-equity ratio. The company said that SEBI has advised the firm against proceeding with the share buyback. Notably, SEBI has cancelled the buyback offer, since the ratio of the aggregate of secured and unsecured debts owed by the company after buyback (assuming full acceptance) would be more than twice the paid-up capital and free reserves of the company based on consolidated financial statements. Pharma major Lupin on Monday, announced that it has received the US health regulators approval to market its Levothyroxine Sodium tablets USP (25mg, 50mg, 75mg, 88mg, 100mg, 112mg, 125mg, 137mg, 150mg, 175mg, 200mg, and 300mg). The approval from the United States Food and Drug Administration (USFDA) is to market the generic version of AbbVie Inc's Synthroid Tablets. Lupin's Levothyroxine Sodium tablets USP is indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), (hypothalamic) congenital, or acquired hypothyroidism. and tertiary ! South Indian Bank slips 8% after Q3FY19 PAT declines 27% Shares of South Indian Bank slipped 8% on the BSE on Monday after the bank's net profit in Q3FY19 declined 27% to Rs83.8cr. It had stood at Rs115cr in the same period of the previous fiscal. The banks total operating income in the quarter rose 10% to Rs1, 735cr as against Rs1, 576.9cr during the previous quarter ended December 2017. ! RBI approves Vaidyanathan as CEO of IDFC First Bank for 3 years The Reserve Bank of India has given its approval for the appointment of V. Vaidyanathan as the Managing Director & CEO of IDFC Bank for a period of 3 (three) years effective the date of his taking charge, i.e., December 19, 2018. IDFC First Bank Ltd is currently trading at Rs47.25 up by Rs0.2 or 0.43% from its previous closing of Rs47.05 on the BSE. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NAME OF THE STOCK : KOTAKBANK DATE : 22/01/2019 SEGMENT : CASH CHART TYPE : Candlestick EXCHANGE : NSE TECHNICAL INDICATORS USED : VOLUME.MACD,RSI. CHART INVESTMENT ADVICE: CALL CS CALL :- BUY KOTAKBANK IN CASH ABOVE 1276 TGT 1300 SL 1252 RATIONALE FOR ARRIVING INVESTMENT ADVICE : TECHNICAL VIEW : THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF TREND REVERSAL IS THERE. OTHER REASON IF ANY :- SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. Capitalstars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Contact us :- 9977499927, 9039012727 Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

8. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Intraday stock tips Financial advisory company Share market company Stock Tips * Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. * CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.